Related Experiment Video
Updated: Sep 16, 2026
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Discovery and Evaluation of 6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinoline Derivatives as P-gp Inhibitors to Overcome
Wen-Jing Lai1,2, Chun-Ling Guo1,2, Jin-Yu Xia1,2
1College of Chemistry and Environmental Engineering, Sichuan University of Science and Engineering, Zigong, China.
Abstract:
The efficacy of chemotherapy against malignant tumors is severely limited by multidrug resistance (MDR), of which the overexpression of P-glycoprotein (P-gp) is recognized as a key mechanism. Consequently, the development of potent, low-toxicity P-gp inhibitors represents a crucial direction in anticancer drug research. Based on our group's prior work on P-gp inhibitors and supported by molecular docking analysis, 21 novel tetrahydroisoquinoline derivatives were designed and synthesized in this study. Their ability to reverse MDR was assessed in the human esophageal carcinoma multidrug-resistant cell line Eca109/VCR. The most active compound 21 demonstrated a superior reversal fold (RF = 654) compared to the third-generation P-gp inhibitor TQ, as confirmed by colony formation and flow cytometry assays. Mechanistic investigations, including chemosensitization, intracellular fluorescent substrate accumulation, and molecular docking studies, verified that the MDR reversal effect of compound 21 is mediated through P-gp inhibition. This work provides a new strategic direction for developing tetrahydroisoquinoline-based sensitizers to overcome tumor drug resistance.
Insights
Researchers developed novel tetrahydroisoquinoline compounds to combat chemotherapy resistance in cancer. Compound 21 effectively reversed multidrug resistance (MDR) by inhibiting P-glycoprotein (P-gp), offering a new strategy against tumor drug resistance.
Area of Science:
- Medicinal Chemistry
- Molecular Pharmacology
- Oncology
Background:
- Multidrug resistance (MDR) limits chemotherapy efficacy in malignant tumors.
- Overexpression of P-glycoprotein (P-gp) is a primary mechanism driving MDR.
- Developing potent, low-toxicity P-gp inhibitors is critical for anticancer drug research.
Purpose of the Study:
- To design and synthesize novel tetrahydroisoquinoline derivatives as potential P-gp inhibitors.
- To evaluate the ability of these compounds to reverse MDR in cancer cells.
- To investigate the mechanism by which MDR reversal is achieved.
Main Methods:
- Synthesis of 21 novel tetrahydroisoquinoline derivatives.
- Assessment of MDR reversal in the Eca109/VCR human esophageal carcinoma cell line.
- Utilized colony formation assays, flow cytometry, and mechanistic studies (chemosensitization, substrate accumulation, molecular docking).
Main Results:
- Compound 21 exhibited significant MDR reversal activity with a reversal fold (RF) of 654.
- This activity was superior to the third-generation P-gp inhibitor TQ.
- Mechanistic studies confirmed that compound 21 inhibits P-gp, mediating the observed MDR reversal.
Conclusions:
- Novel tetrahydroisoquinoline derivatives show promise as P-gp inhibitors.
- Compound 21 is a potent MDR reversal agent, offering a new therapeutic strategy.
- Tetrahydroisoquinoline-based sensitizers represent a viable approach to overcome tumor drug resistance.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
